Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FORTRESS BIOTECH, INC.

(FBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fortress Biotech : and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition

10/11/2021 | 07:39am EST

NEW YORK and SOLANA BEACH, Calif. - Cyprium Therapeutics, Inc. ('Cyprium'), a Fortress Biotech, Inc. (Nasdaq: FBIO) ('Fortress') partner company, with support from its licensing partner Sentynl Therapeutics, Inc. ('Sentynl'), a wholly owned subsidiary of Cadila Healthcare Limited ('Zydus'), announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate (CuHis). In both pre-specified primary and secondary efficacy analyses, treatment with CUTX-101 demonstrated a significantly greater median overall survival (OS) compared to untreated historical control patients. These data will be presented as a virtual poster at the 2021 American Academy of Pediatrics National Conference & Exhibition. More information on the poster is listed below:

Virtual Poster Title: Copper Histidinate Treatment for Menkes Disease (Kinky Hair Syndrome)

Presentation Date: Friday, October 08, 2021

Session: (VH1410) Section on Advances in Therapeutics and Technology Program

Authors: Stephen G. Kaler, M.D., M.P.H., Shama Munim, M.S., Michael Chen, Ph.D., Robert Niecestro, Ph.D., Lung S. Yam, M.D., Ph.D.

'There is a significant unmet need for an approved treatment for patients with Menkes disease. These positive data demonstrate the potential of CUTX-101 to be an effective therapy for patients with this devastating disease. We look forward to working with the U.S. Food and Drug Administration ('FDA') to begin our rolling submission of a new drug application ('NDA') for CUTX-101 in the fourth quarter of this year,' said Lung S. Yam, M.D., Ph.D., President and Chief Executive Officer of Cyprium.

In two completed open-label, single-arm, single-site studies, 129 patients with Menkes disease were treated with CUTX-101 (1450 mcg CUTX-101, equivalent to 250 mcg elemental copper) administered subcutaneously twice daily until 12 months of age, and once daily thereafter, for a total duration of up to three years. Sixty-six patients born after 1999 and with severe loss-of-function ATP7A mutations from these two studies were combined and categorized into an Early Treatment cohort (CuHis-ET; treatment initiated within 4 weeks of birth, corrected for prematurity, n=31) and a Late Treatment cohort (CuHis-LT; treatment initiated after 4 weeks of birth, n=35). A historical control cohort of 18 Menkes disease patients who had not been treated with CUTX-101 were enrolled (including 18 in historical control-early treatment cohort (HC-ET); 17 of whom were also included in historical control-late treatment (HC-LT)). Efficacy of CUTX-101 was assessed by comparing CuHis-ET to untreated HC-ET, and CuHis-LT to untreated HC-LT, using OS as the primary and secondary efficacy endpoints, respectively.

The primary efficacy endpoint comparing CuHis-ET to HC-ET and the secondary efficacy endpoint comparing CuHis-LT to HC-LT were both met. Overall, a 79% reduction in risk of death was observed in CuHis-ET patients compared with HC-ET patients and median OS was 177.1 and 16.1 months, respectively with a hazard ratio (HR) of (95% CI) = 0.208 (0.094, 0.463) p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about FORTRESS BIOTECH, INC.
11/29Journey Medical Corporation Introduces Expanded Board of Directors
AQ
11/18Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Opti..
AQ
11/16Journey Medical Corporation Announces Closing of Initial Public Offering
GL
11/15FORTRESS BIOTECH : Reports Record Third Quarter 2021 Financial Results and Recent Corporat..
PU
11/15FORTRESS BIOTECH : Q3 Earnings Snapshot
AQ
11/15FORTRESS BIOTECH, INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/15Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 EPS $0.54
MT
11/15Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corpora..
GL
11/15Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q3 Revenue $21.1M
MT
11/15Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
More news
Analyst Recommendations on FORTRESS BIOTECH, INC.
More recommendations
Financials (USD)
Sales 2021 95,0 M - -
Net income 2021 -26,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,31x
Yield 2021 -
Capitalization 284 M 284 M -
Capi. / Sales 2021 2,99x
Capi. / Sales 2022 2,38x
Nbr of Employees 111
Free-Float 70,2%
Chart FORTRESS BIOTECH, INC.
Duration : Period :
Fortress Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FORTRESS BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,66 $
Average target price 7,60 $
Spread / Average Target 186%
EPS Revisions
Managers and Directors
Lindsay Allan Rosenwald Chairman, President & Chief Executive Officer
Robyn M. Hunter Chief Financial Officer, Secretary & Treasurer
Jimmie Harvey Independent Director
J. Jay Lobell Independent Director
Malcolm I. Hoenlein Independent Director
Sector and Competitors
1st jan.Capi. (M$)
FORTRESS BIOTECH, INC.-16.09%284
CSL LIMITED9.18%99 188
WUXI BIOLOGICS (CAYMAN) INC.4.77%57 826
SAMSUNG BIOLOGICS CO.,LTD.7.87%49 556
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-3.72%34 628